Clinical trials: Tick-Borne Encephalitis
Encephalitis, Tick-Borne
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
The purpose of this study it is to evalutate the persistence of antibodies after a booster immunisation with a TBE vaccine for adults
- Trial name
- NCT00311493
- Testing
- Tick-Borne Encephalitis vaccine
- Where
- Germany
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Novartis
Encephalitis, Tick-Borne
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
The purpose of this study is to evaluate the safety, immunogenicity and tolerability of TBE vaccines administered to children.
- Trial name
- NCT00311441
- Testing
- Tick-Borne Encephalitis vaccine
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Novartis
Tick-Borne Encephalitis
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
- Trial name
- NCT04648241
- Testing
- TBE vaccine 0.5 mL, TBE vaccine 0.25 mL
- Where
- 6 sites in Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine in healthy children aged 1 to 6 years.
- Trial name
- NCT00161772
- Testing
- Tick-borne Encephalitis Vaccine
- Where
- 23 sites in Austria, Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Tick Borne Encephalitis, Virus Diseases
Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
The aim of this study is to investigate the immunogenicity response in adults up to 10 years after one booster dose. Data collected from this study will allow for greater information to prescribers who administer TBE vaccine, so…
- Trial name
- NCT01562444
- Testing
- Blood draw
- Where
- Czechia
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Encephalitis, Tick-Borne
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
The objective of this study is to assess the immunogenicity, safety and interchangeability of two different TBE vaccines in children aged 1-11 years, the first and second vaccination with either FSME-IMMUN 0.25ml Junior or…
- Trial name
- NCT00840801
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Pfizer
The Tick-borne Encephalitis Virus (TBEV)
First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of the investigational monoclonal antibody TBE025 when given intravenously to healthy adult volunteers aged 18 to 55.
- Trial name
- SVRI01 (NCT07377253)
- Testing
- Human monoclonal antibody TBE025, intravenous infusion
- Where
- Switzerland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Giuseppe Pantaleo
Tick-borne Encephalitis
Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination
The phenomenon of no- and low-responsiveness has been described after applications of different vaccines (e.g. hepatitis B, TBE) and is concerning about 2-10% of the vaccinees.
- Trial name
- NCT00804219
- Testing
- TBE vaccination and influenza vaccination
- Where
- Austria
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Tick-borne Encephalitis (TBE)
TBE Seropersistence up to 10 Years After First Booster in Adults
The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.
- Trial name
- NCT01582698
- Testing
- FSME-IMMUN 0.5 ml
- Where
- 2 sites in Poland
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all subjects who completed two vaccinations in one of the three…
- Trial name
- NCT00161850
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 25 sites in Austria, Germany
- Volunteers
- 615 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick Borne Encephalitis
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Patients undergoing allogeneic blood and marrow transplantation (HSCT) experience a prolonged period of dysfunctional immunity. Systematic reimmunization is necessary at appropriate time intervals following transplantation to…
- Trial name
- NCT01991067
- Testing
- TBE virus vaccine
- Where
- Austria
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Tick-Borne Encephalitis
Dexamethasone in Tick-borne Encephalitis
The purpose of this study is to investigate the efficacy of dexamethasone in patients with tick-borne encephalitis.
- Trial name
- NCT07584525
- Testing
- Dexametasone, Saline (0.9% NaCl)
- Where
- Slovenia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Encephalitis, Tick-borne
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations…
- Trial name
- NCT00161954
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
The purpose of this study is to assess: TBE antibody persistence 24, 34, 46 and 58 months (as applicable) after the first booster TBE vaccination with FSME-IMMUN 0.5ml given in Study 223, by means of ELISA (IMMUNOZYM FSME IgG)…
- Trial name
- NCT00503529
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 2 sites in Poland
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
The risk for tick borne encephalitis increases in Sweden. Together with an increased awareness of the possibility to acquire protection by vaccination, this has led to an increase in the number of doses of the vaccine distributed…
- Trial name
- NCT02318069
- Testing
- FSME-immune
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sormland County Council, Sweden
Tick-Borne Encephalitis
Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
Many viral infections of global importance, including HIV, are transmitted across the mucosal surface of the genital tract. As immunity against these infections is likely to be primarily mediated by antibodies in mucosal…
- Trial name
- CRC306 (NCT01710189)
- Testing
- TicoVac
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Tick Borne Encephalitis
Tick-borne Encephalitis and Borrelial Antibodies in Serum
In Slovenia, tick-borne encephalitis and Lyme borreliosis are both endemic diseases with high incidence rates and they are both transmitted by a bite of infected Ixodes ricinus tick.
- Trial name
- NCT03956446
- Testing
- Doxycycline, Symptomatic therapy, Questionnaire
- Where
- Slovenia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Encephalitis, Tick-borne
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in…
- Trial name
- NCT00161746
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
The objective of this study is to assess the TBE antibody persistence approximately three years after administration of a TBE booster vaccination with FSME-IMMUN 0.25 ml Junior in children who received either 0.25 mL or 0.5 mL…
- Trial name
- NCT00163618
- Testing
- Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
- Where
- 4 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
The objective of this study is to investigate the immunogenicity and safety of FSME-IMMUN 0.5 ml in two age strata (stratum A: 16 to 49 years, stratum B: > 50 years), with the first and second vaccinations being administered…
- Trial name
- NCT00460486
- Testing
- Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
- Where
- 4 sites in Poland
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Pfizer